Skip to main content
Signal8
Launch Terminal

Pharvaris N.V. (PHVS)

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Pharvaris N.V. logo

Pharvaris N.V.

NASDAQ:PHVSHealthcare
-0.15%$33.53
AH$34.68+3.43%vs close
Mkt Cap$2.35B
Float38.06M
O/S70.2M
Vol
$ Vol
RVOL
Inst Own91.8%
SI6.5%
Earnings
Dilution
Pharvaris N.V. logoNASDAQ:PHVS$33.53-0.15%
Upcoming Catalysts
  • deucrictibant IRPDUFA
    on-demand treatment of HAE attacks
    Cash runway at this date: 19mo
    Apr 23, 2027in 172 days8-K
Phase Distribution
8 lead-sponsored trials·4 active·2 completed
Phase 22
Phase 2/31
Phase 34
Not applicable1
(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

    Deucrictibant, Placebo

    Hereditary Angioedema, Hereditary Angioedema Type I +12

    Enrollment
    134
    Start
    Feb 2024
    Primary Completion
    Oct 2025
    Completion
    Oct 2025
    NCT06343779
  • Phase 3
    Active, not recruiting

    Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

    Deucrictibant, Placebo

    Hereditary Angioedema (HAE)

    Enrollment
    81
    Start
    Dec 2024
    Primary Completion
    Aug 2026est.
    Completion
    Aug 2026est.
    NCT06669754
  • Phase 3
    Enrolling by invitation

    Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

    Deucrictibant

    Hereditary Angioedema (HAE)

    Enrollment
    170
    Start
    Feb 2025
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2028est.
    NCT06679881
  • Phase 3
    Recruiting

    Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

    Deucrictibant, Placebo

    Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)

    Enrollment
    48
    Start
    Oct 2025
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2027est.
    NCT07266805
  • Phase 2/3
    Enrolling by invitation

    Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

    deucrictibant, deucrictibant

    Hereditary Angioedema, Hereditary Angioedema Type I +15

    Enrollment
    150
    Start
    Dec 2022
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2027est.
    NCT05396105
  • Phase 2
    Completed

    Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

    Deucrictibant, Placebo

    Hereditary Angioedema, Hereditary Angioedema Type I +8

    Enrollment
    74
    Start
    Feb 2021
    Primary Completion
    Sep 2022
    Completion
    Mar 2023
    NCT04618211
  • Phase 2
    Terminated

    Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

    Deucrictibant low dose, Deucrictibant high dose

    Hereditary Angioedema, Hereditary Angioedema Type I +8

    Enrollment
    34
    Start
    Apr 2022
    Primary Completion
    Jun 2025
    Completion
    Jun 2025
    NCT05047185
  • Expanded access
    Available

    EAP for Deucrictibant Immediate-release

    Deucrictibant IR

    Hereditary Angioedema

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT07759141
Search ClinicalTrials.gov for “Pharvaris”